NCT04752215 - A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

November 19, 2024

Study Completion Date

November 19, 2024

Conditions

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms

Interventions

DRUG

BI 765049

DRUG

ezabenlimab

Trial Locations (14)

10016

New York University Langone Medical Center, New York

32806

MD Anderson Cancer Center Orlando, Orlando

34232

Florida Cancer Specialists-Sarasota-61670, Sarasota

35294

University of Alabama at Birmingham, Birmingham

37203

Tennessee Oncology, PLLC-Nashville-52568, Nashville

40202

Norton Healthcare - Norton Cancer Institute - Louisville, Louisville

60611

Northwestern University, Chicago

73104

Stephenson Cancer Center, Oklahoma City

75230

Mary Crowley Cancer Research Center, Dallas

75246

Baylor University Medical Center, Dallas

80218

HealthONE, Denver

90067

Valkyrie Clinical Trials, Los Angeles

92868

University of California Irvine, Orange

M5G 1Z5

Princess Margaret Cancer Centre, Toronto